16^th Global Summit on Immunology and Cell Biology April 17-18, 2023 Rome, Italy

Charles J Malemud received the PhD from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. He is Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory at Case Western Reserve University School of Medicine. He has published more than 200 papers and reviews primarily in the field of chondrocyte biology. He is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology.

Clinical and Cellular Immunology

Michael Tainsky is a molecular cell biologist who has been studying the molecular basis of human cancer for more than 30 years. In 1998, he came to the Karmanos Cancer Institute at Wayne State University School of Medicine after 13 years on the faculty of the University of Texas, M.D. Anderson Cancer Center in Houston, TX, and 8 years at NCI/NIH. He has studied the biological effects of oncogenes, tumor suppressor genes, and transcription factor on tumor cells; and in the Li-Fraumeni Cancer Syndrome, he studied the mechanisms of cellular immortalization. Recently, he extended his mechanistic cancer research to translational applications of genomics and proteomics to molecular diagnostics of ovarian cancer. For the past 10 years, his laboratory team has developed the epitope cloning technology and protein microarray immunoassays to detect tumor autoantibodies in patients’ sera. His Epitomics Biomarker Technology identifies the autoantigen biomarkers using novel informatics tools for the classification of patients. In 2009, he published a 330-page book as editor in the Methods in Molecular Biology Series from Humana Press entitled Tumor Biomarker Discovery. He was invited to guest edit Special Issues of the journal Cancer Biomarkers on Antibody Biomarkers and Biomarkers in Ovarian Cancer. Dr. Tainsky holds the Barbara and Fred Erb Chair in Cancer Genetics at the Barbara Ann Karmanos Cancer Institute. He is a professor in the Department of Oncology.

molecular cell biology

Ahmed Hegazi (or Ahmed Gaffer Hegazi; احمد جعفر حجازى) (born May 31, 1948) is currently a Professor of Microbiology and Immunology in the department of Zoonotic Diseases, National Research Center, Egypt. Prof. Hegazi received his masters degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi Organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 166 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Awards First Class Decoration of Excellence, Egypt, 1995 The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996 The National Scientific Prize In Biological Sciences, Egypt, 1990 The Scientific Prize of The National Research Center, Cairo, Egypt, 1989 The Second Best Research Paper Award, International Congress of Propolis, Bones Airs, Argentina, 2000 Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Patents Patent No. 8901 at 22/08/2006: A novel drug from natural products with new therapeutic modalities in treatment of psoriasis Patent No. 1005 at 02/01/2006: A novel drug from natural resources for controlling Fascioliasis Patent No. 270: at 01/06/2005: A novel drug from medicinal plants with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Patent No. 272: at 01/06/2005: A novel drug from natural resources with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties.

Immunology and Microbiology